Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
出版年份 2019 全文链接
标题
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
作者
关键词
CCR2 inhibitor, Pancreatic cancer, Immuno-oncology, Tumor-infiltrating macrophages, Tumor-infiltrating cells
出版物
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-07-12
DOI
10.1007/s10637-019-00830-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future
- (2018) Adrian M. J. Pokorny et al. INTERNAL MEDICINE JOURNAL
- Targeting both tumour-associated CXCR2+neutrophils and CCR2+macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma
- (2017) Timothy M Nywening et al. GUT
- Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
- (2017) Aleksandra Adamska et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma—An Infrequent Event: Elucidation of Risk Factors and Management Implications
- (2016) Ibrahim Halil Sahin et al. Clinical Colorectal Cancer
- Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
- (2016) Timothy M Nywening et al. LANCET ONCOLOGY
- Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies
- (2015) E. Gabriela Chiorean et al. Drug Design Development and Therapy
- Pancreatic Adenocarcinoma
- (2015) David P. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy
- (2014) Jacek Rolinski et al. Journal of Immunotoxicology
- Tumor microenvironment profoundly modifies functional status of macrophages: Peritoneal and tumor-associated macrophages are two very different subpopulations
- (2013) Dayron Rodríguez et al. CELLULAR IMMUNOLOGY
- Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
- (2013) D. E. Sanford et al. CLINICAL CANCER RESEARCH
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
- (2012) J. B. Mitchem et al. CANCER RESEARCH
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
- (2010) Suzanne Ostrand-Rosenberg CANCER IMMUNOLOGY IMMUNOTHERAPY
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
- (2009) M. K. Srivastava et al. CANCER RESEARCH
- Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
- (2009) S. Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
- (2008) C. Marcela Diaz-Montero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CANCER IMMUNOLOGY: Cancer's Bulwark Against Immune Attack: MDS Cells
- (2008) J. Marx SCIENCE
- Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice
- (2007) Mitsuhisa Koga et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search